Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P35227
UPID:
PCGF2_HUMAN
Alternative names:
DNA-binding protein Mel-18; RING finger protein 110; Zinc finger protein 144
Alternative UPACC:
P35227; A6NGD8
Background:
Polycomb group RING finger protein 2, also known as Mel-18 and RING finger protein 110, plays a pivotal role in transcriptional repression, binding specifically to DNA sequences to regulate cell proliferation and neural development. It is a key component of the Polycomb group (PcG) multiprotein PRC1-like complex, crucial for maintaining genes in a transcriptionally repressive state through chromatin remodeling and histone modification.
Therapeutic significance:
The protein's involvement in Turnpenny-Fry syndrome, characterized by a spectrum of developmental anomalies, underscores its clinical relevance. Understanding the role of Polycomb group RING finger protein 2 could open doors to potential therapeutic strategies for managing this syndrome and related developmental disorders.